Cd161-clec2d

(pdf) blocking llt1 (clec2d, ocil)-nkrp1a (cd161) interaction enhances Ocil prostate overexpression mediated inhibits cd161 nk cells Mediated blocking negative killer triple cells enhances lysis interaction breast cancer cell natural

(PDF) Blocking LLT1 (CLEC2D, OCIL)-NKRP1A (CD161) interaction enhances

(PDF) Blocking LLT1 (CLEC2D, OCIL)-NKRP1A (CD161) interaction enhances

Ocil blocking mediated killer lysis cd161 enhances tnbc Cd63 antibody immunofluorescence fitc ma1 mem monoclonal icc Cd103+cd11b+ mucosal classical dendritic cells initiate long-term

Figure 1 from overexpression of llt1 (ocil, clec2d) on prostate cancer

(pdf) blocking llt1 (clec2d, ocil)-nkrp1a (cd161) interaction enhancesFigure 1 from overexpression of llt1 (ocil, clec2d) on prostate cancer Cd63 antibody, fitc (ma1-19602)Cd11b cd103 cells dendritic mucosal.

Prostate cancer nk interaction .

(PDF) Blocking LLT1 (CLEC2D, OCIL)-NKRP1A (CD161) interaction enhances

Figure 1 from Overexpression of LLT1 (OCIL, CLEC2D) on prostate cancer

Figure 1 from Overexpression of LLT1 (OCIL, CLEC2D) on prostate cancer

Figure 1 from Overexpression of LLT1 (OCIL, CLEC2D) on prostate cancer

Figure 1 from Overexpression of LLT1 (OCIL, CLEC2D) on prostate cancer

(PDF) Blocking LLT1 (CLEC2D, OCIL)-NKRP1A (CD161) interaction enhances

(PDF) Blocking LLT1 (CLEC2D, OCIL)-NKRP1A (CD161) interaction enhances

CD103+CD11b+ mucosal classical dendritic cells initiate long-term

CD103+CD11b+ mucosal classical dendritic cells initiate long-term

CD63 Antibody, FITC (MA1-19602)

CD63 Antibody, FITC (MA1-19602)